Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-P16-093 vs 68Ga-PSMA-11 in Primary Prostate Cancer
NCT05324332Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of 68Ga-P16-093 in prostate cancer (PCa), sponsored by Peking Union Medical College Hospital. Primary endpoint: Tumor detection rate at 1 year. Started Apr 2022; status: recruiting.
02
Drugs
68Ga-P16-093
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05324332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05324332.